Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. LGVN
LGVN logo

LGVN Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Longeveron Inc (LGVN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
0.970
1 Day change
8.95%
52 Week Range
1.830
Analysis Updated At
2026/03/20
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Longeveron Inc (LGVN) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available. While the stock has shown a significant regular market price increase of 13.71%, technical indicators like RSI suggest the stock is overbought, and the company's financial performance remains weak with declining revenue and increased net loss. The lack of strong positive catalysts, recent trading signals, or significant insider/congressional activity further supports a hold recommendation.

Technical Analysis

The MACD is positive and expanding, indicating bullish momentum. However, the RSI is at 80.635, signaling an overbought condition. The stock is trading near its resistance level (R1: 1.131), suggesting limited upside potential in the short term. Moving averages are converging, indicating no clear trend.

Positive Catalysts

  • Gross margin has improved slightly YoY.

Neutral/Negative Catalysts

  • RSI indicates the stock is overbought. Revenue has declined significantly (-82.28% YoY), and the company reported a substantial net loss of $22.7 million in FY. No significant hedge fund, insider, or congressional trading activity. The stock has a 70% chance to decline slightly (-0.05%) the next day and -5.6% in the next month.

Financial Performance

In Q3 2025, revenue dropped significantly by 82.28% YoY to $137,000. Net income improved YoY but remains negative at -$7.22 million. EPS improved slightly to -0.39, and gross margin increased to 91.24%. Overall, financial performance is weak with no clear growth trajectory.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Roth Capital lowered the price target from $3 to $2 but maintained a Buy rating. Analysts expect potential positive data from the ELPIS II study in Q3 2026, with a BLA filing anticipated in 2027.

Wall Street analysts forecast LGVN stock price to rise
2 Analyst Rating
Wall Street analysts forecast LGVN stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.893
sliders
Low
3
Averages
3.5
High
4
Current: 0.893
sliders
Low
3
Averages
3.5
High
4
Roth Capital
Buy
downgrade
$3 -> $2
AI Analysis
2026-03-18
Reason
Roth Capital
Price Target
$3 -> $2
AI Analysis
2026-03-18
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on Longeveron to $2 from $3 but keeps a Buy rating on the shares. The firm continues to expect top-line data from the ELPIS II study evaluating Laromestrocel in HLHS - hypoplastic left heart syndrome - patients in Q3 of this year, and if positive, a BLA filing is expected to occur in 2027, the analyst tells investors in a research note.
Roth Capital
Buy
downgrade
$10 -> $3
2025-08-15
Reason
Roth Capital
Price Target
$10 -> $3
2025-08-15
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on Longeveron to $3 from $10 and keeps a Buy rating on the shares. The firm's price target cut reflects Q2 results and the dilutive equity financing earlier this week, though Longeveron remains an underappreciated firm despite its first-mover advantage in HLHS, or Hypoplastic Left Heart Syndrome, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for LGVN
Unlock Now

People Also Watch